Results 1 to 10 of about 14,279 (236)

Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer [PDF]

Cancer Medicine, 2023
Background Peroxisome proliferator‐activated receptor agonists such as fibrates restore oxidative metabolism in cytotoxic T‐lymphocytes, thereby enhancing response to immune checkpoint inhibitors (ICI) in preclinical models. However, there is no evidence
William A. Stokes, Madhusmita Behera, Renjian Jiang, David A. Gutman, Zhonglu Huang, Abigail Burns, Nikhil T. Sebastian, Vidula Sukhatme, Michael C. Lowe, Suresh S. Ramalingam, Vikas P. Sukhatme, Drew Moghanaki   +11 more
doaj   +2 more sources

Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes? [PDF]

Journal of Research in Medical Sciences
Diabetic kidney disease (DKD) affects 30%–40% of patients with diabetes mellitus (DM). Dyslipidemia is a key modifiable risk factor for the development and progression of DKD.
Mohammad Reza Chitsazi, Farzad Safari, Elena Malekpour, Seyed Arsham Mirzaei, Mohammad Hossein Shafieyoun, Faraz Golafshan, Hanieh Rouzbahani, Mohadese Nekookhoo, Ali Noursina, Mansour Siavash   +9 more
doaj   +2 more sources

Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses [PDF]

Frontiers in Pharmacology
BackgroundPrimary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive cholestasis. Although ursodeoxycholic acid (UDCA) is the standard therapy, a substantial proportion of patients show inadequate response ...
Jian Zhang, Ting Xiu, Qi Shen
doaj   +2 more sources

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Metabolites, 2023
Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events.
Shizuya Yamashita, Manfredi Rizzo, Ta-Chen Su, Daisaku Masuda   +3 more
doaj   +1 more source

Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis. [PDF]

PLoS ONE, 2018
Conventional wisdom supports prescribing "fibrates before statins", that is, prioritizing treatment of hypertriglyceridemia (hTG) to prevent pancreatitis ahead of low-density lipoprotein cholesterol to prevent coronary heart disease.
Laurel A Copeland, C Scott Swendsen, Dawn M Sears, Andrea A MacCarthy, Catherine J McNeal   +4 more
doaj   +1 more source

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing

Annals of Medicine, 2022
Based on separate protective mechanisms related to lipid metabolism, viral cell entry and inflammation, fibrate treatment might be advantageous among patients who have been taking fibrates before SARS-CoV-2 infection and continue taking them during the ...
Alpo Vuorio, Jonas Brinck, Petri T. Kovanen   +2 more
doaj   +1 more source

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

iScience, 2020
Summary: Most triacylglycerol-lowering fibrates have been developed in the 1960s–1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified.
Shotaro Kamata, Takuji Oyama, Kenta Saito, Akihiro Honda, Yume Yamamoto, Keisuke Suda, Ryo Ishikawa, Toshimasa Itoh, Yasuo Watanabe, Takahiro Shibata, Koji Uchida, Makoto Suematsu, Isao Ishii   +12 more
doaj   +1 more source

Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study

Frontiers in Cardiovascular Medicine, 2022
BackgroundAlthough a recent study reported that fibrates are associated with a low risk of cardiovascular (CV) death and can postpone the need for long-term hemodialysis in patients with advanced chronic kidney disease (CKD), little is known regarding ...
Wen-Yu Ho, Chieh-Li Yen, Chieh-Li Yen, Cheng-Chia Lee, Cheng-Chia Lee, Yi-Ran Tu, Yi-Ran Tu, Chao-Yu Chen, Chao-Yu Chen, Ching-Chung Hsiao, Ching-Chung Hsiao, Pao-Hsien Chu, Pao-Hsien Chu, Hsiang-Hao Hsu, Hsiang-Hao Hsu, Ya-Chun Tian, Ya-Chun Tian, Chih-Hsiang Chang, Chih-Hsiang Chang   +18 more
doaj   +1 more source

Lipid Messenger Phosphatidylinositol-4,5-Bisphosphate Is Increased by Both PPARα Activators and Inhibitors: Relevance for Intestinal Cell Differentiation

Biology, 2022
We investigated the effects of PPARα activators fenofibrate and WY-14643 as well as the PPARα inhibitor GW6471 on the PI3K/Akt/PTEN pathway of intestinal cell differentiation. Our previous study showed that all these compounds increased the expression of
Katerina Cizkova, Katerina Koubova, Zdenek Tauber   +2 more
doaj   +1 more source

Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet

Frontiers in Nutrition, 2022
Obesity is characterized by lipid accumulation in distinct organs. Presently, fenofibrate is a commonly used triglyceride-lowering drug. This study is designed to investigate whether long-term fenofibrate intervention can attenuate lipid accumulation in ...
Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Yan-Hong Si, Shou-Dong Guo   +6 more
doaj   +1 more source